Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220972885> ?p ?o ?g. }
- W4220972885 endingPage "498" @default.
- W4220972885 startingPage "491" @default.
- W4220972885 abstract "Immune check point inhibitors (ICIs) have marked their existence in the field of cancer immunotherapy. Their existence dates to 2011 when the first anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) got its FDA approval for the management of metastatic melanoma. The class of ICIs now also include antibodies against programmed cell death-1 (PD-1) and its ligand (PD-L1) which immediately gained FDA approval for use against multiple cancer types because of their effect on patient survival. These discoveries were followed by a significant rise in the identification of novel ICIs with potential anti-tumor response. Researchers have identified various novel checkpoint inhibitors which are currently under clinical trials. Despite the success of ICIs, only a small subset of patients with specific tumor types achieves a promising response. Not only efficient therapeutic response but also development of resistance, recurrence and other immune-related adverse effects limit the applicability of immune checkpoint inhibitors. These challenges can only be addressed when a directed approach is implemented at both basic and translational level. In this review, we have briefly discussed the history of ICIs, the next generation of inhibitors which are currently under clinical trial and mechanisms of resistance that can lead to treatment failure. Ultimately, by combining these insights researchers might be able to achieve a more durable and effective response in cancer patients." @default.
- W4220972885 created "2022-04-03" @default.
- W4220972885 creator A5011815298 @default.
- W4220972885 creator A5022942037 @default.
- W4220972885 creator A5050380519 @default.
- W4220972885 creator A5065614169 @default.
- W4220972885 creator A5075280225 @default.
- W4220972885 date "2022-11-01" @default.
- W4220972885 modified "2023-09-30" @default.
- W4220972885 title "The evolutionary legacy of immune checkpoint inhibitors" @default.
- W4220972885 cites W1940241680 @default.
- W4220972885 cites W1967727543 @default.
- W4220972885 cites W1975130471 @default.
- W4220972885 cites W1982488143 @default.
- W4220972885 cites W1991235944 @default.
- W4220972885 cites W2020329594 @default.
- W4220972885 cites W2049209548 @default.
- W4220972885 cites W2069598912 @default.
- W4220972885 cites W2094366129 @default.
- W4220972885 cites W2097995306 @default.
- W4220972885 cites W2100184048 @default.
- W4220972885 cites W2103021272 @default.
- W4220972885 cites W2112121482 @default.
- W4220972885 cites W2112601576 @default.
- W4220972885 cites W2123363005 @default.
- W4220972885 cites W2133075384 @default.
- W4220972885 cites W2142804723 @default.
- W4220972885 cites W2152897456 @default.
- W4220972885 cites W2261307795 @default.
- W4220972885 cites W2263759961 @default.
- W4220972885 cites W2407062242 @default.
- W4220972885 cites W2465860350 @default.
- W4220972885 cites W2522313999 @default.
- W4220972885 cites W2529896336 @default.
- W4220972885 cites W2557336488 @default.
- W4220972885 cites W2560185130 @default.
- W4220972885 cites W2573158190 @default.
- W4220972885 cites W2591493010 @default.
- W4220972885 cites W2593111137 @default.
- W4220972885 cites W2600581432 @default.
- W4220972885 cites W2607904950 @default.
- W4220972885 cites W2622499649 @default.
- W4220972885 cites W2707748297 @default.
- W4220972885 cites W2753065806 @default.
- W4220972885 cites W2753432434 @default.
- W4220972885 cites W2761586559 @default.
- W4220972885 cites W2767343890 @default.
- W4220972885 cites W2782124401 @default.
- W4220972885 cites W2799553179 @default.
- W4220972885 cites W2802645166 @default.
- W4220972885 cites W2884091495 @default.
- W4220972885 cites W2889697240 @default.
- W4220972885 cites W2902856530 @default.
- W4220972885 cites W2904099327 @default.
- W4220972885 cites W2904444972 @default.
- W4220972885 cites W2904723051 @default.
- W4220972885 cites W2905817704 @default.
- W4220972885 cites W2906298070 @default.
- W4220972885 cites W2910994117 @default.
- W4220972885 cites W2913392426 @default.
- W4220972885 cites W2919147181 @default.
- W4220972885 cites W2920270836 @default.
- W4220972885 cites W2943781197 @default.
- W4220972885 cites W2945219971 @default.
- W4220972885 cites W2947019869 @default.
- W4220972885 cites W2947747173 @default.
- W4220972885 cites W2947934006 @default.
- W4220972885 cites W2976744492 @default.
- W4220972885 cites W2979972034 @default.
- W4220972885 cites W2983326574 @default.
- W4220972885 cites W3013352992 @default.
- W4220972885 cites W3015265197 @default.
- W4220972885 cites W3022746266 @default.
- W4220972885 cites W3030448313 @default.
- W4220972885 cites W3038467178 @default.
- W4220972885 cites W3042095160 @default.
- W4220972885 cites W3043942728 @default.
- W4220972885 cites W3083986479 @default.
- W4220972885 cites W3091064661 @default.
- W4220972885 cites W3106005610 @default.
- W4220972885 cites W3110072413 @default.
- W4220972885 cites W3126208996 @default.
- W4220972885 cites W3137310994 @default.
- W4220972885 cites W3138556548 @default.
- W4220972885 cites W3146935595 @default.
- W4220972885 cites W3162772697 @default.
- W4220972885 cites W3171517418 @default.
- W4220972885 cites W3174243617 @default.
- W4220972885 cites W3205998216 @default.
- W4220972885 doi "https://doi.org/10.1016/j.semcancer.2022.03.020" @default.
- W4220972885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35341912" @default.
- W4220972885 hasPublicationYear "2022" @default.
- W4220972885 type Work @default.
- W4220972885 citedByCount "26" @default.
- W4220972885 countsByYear W42209728852022 @default.
- W4220972885 countsByYear W42209728852023 @default.
- W4220972885 crossrefType "journal-article" @default.
- W4220972885 hasAuthorship W4220972885A5011815298 @default.